Solid Biosciences (SLDB) AI Stock Analysis

• Market Cap: $702.51M
• Dividend Yield: N/A
• Average Volume (3M): 1.59M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.92
• Revenue Growth: N/A
• EPS Growth: 17.88%
• Country: US
• Employees: 100
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.53
• Shares Outstanding: 98,391,310
• 10 Day Avg. Volume: 2,271,177
• 30 Day Avg. Volume: 1,592,649
• PEG Ratio: 0.08
• Price to Book (P/B): 2.74
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.13
• Enterprise Value/Market Cap: 0.73
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -409.78
• Enterprise Value/Ebitda: -3.00
• 1Y Price Target: $18.57
• Price Target Upside: 164.15% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): -1.99
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: $7.50 ▲(6.69% Upside)
• Action: Reiterated Date: 03/20/26
• Date: Action: Reiterated 03/20/26

The score is held back primarily by weak financial performance (no revenue, widening losses, and significant cash burn). Offsetting factors include a technically improving trend and meaningful corporate catalysts, particularly the Phase 1/2 Duchenne data and substantial financing that extends runway.

Positive Factors

Precision genetic-medicine focus

A pipeline centered on gene and genetic-medicine approaches targets root causes of DMD rather than symptoms. This strategic focus aligns with durable structural demand for disease-modifying therapies, creating high clinical value and long-term commercial optionality if clinical/regulatory success is achieved.

Low financial leverage

Relatively low debt versus equity provides financial flexibility versus peers in a cash-intensive development stage. Lower leverage reduces near-term solvency risk, preserving optionality to fund trials or seek partnerships without immediate pressure from high interest obligations, supporting sustained R&D investment.

Positive SGT-003 interim data

Interim clinical signals and planned FDA engagement represent a structural inflection point: favorable biomarker and safety data can materially reduce development and regulatory risk, accelerate timelines, enhance partner interest, and improve odds of eventual commercial revenue and durable franchise value.

Negative Factors

No revenue and widening losses

A sustained absence of product revenue and growing operating losses indicate the company remains pre-commercial and value depends entirely on trial outcomes. Persistent negative margins erode equity over time and mean long-term viability hinges on successful commercialization or transformational partnerships.

Heavy and accelerating cash burn

Large negative operating and free cash flows that have worsened year-over-year create an ongoing need for external capital. Recurrent fundraising risks dilution, can delay development programs, and places strategic pressure on management to secure partnerships or approvals to stabilize funding sources.

Funding- and execution-dependent model

The business model depends on successful clinical outcomes, regulatory approvals, partner deals, and scalable gene-therapy manufacturing. These structural execution risks — manufacturing complexity, regulatory hurdles, and partner dependence — can materially delay or derail value creation absent consistent capital and proven operations.

Solid Biosciences Business Overview & Revenue Model

Company Description

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Solid Biosciences is a pre-commercial, clinical-stage biotech and does not have recurring product sales; its business model is primarily to invest in R&D to advance its pipeline and, if successful, seek regulatory approval and eventually commercialize therapies. Historically, revenue has generally been driven by collaboration and license arrangements (e.g., upfront payments, research funding reimbursements/cost sharing, milestone payments tied to development/regulatory/commercial events, and potential royalties on partner sales), when such arrangements are in place; if specific current/active agreements and their economics are not publicly available, the exact partner names, payment amounts, and timing are null. In practice, the company funds operations largely through external financing (primarily issuing equity and other capital-raising transactions), while any reported revenue in its financial statements typically reflects collaboration-related payments rather than sales of approved products. Key factors influencing future earnings potential include clinical trial outcomes, regulatory approvals, manufacturing scalability for gene therapy, and the ability to secure partnerships or, post-approval, to price and sell therapies directly to patients/health systems; current product-sales-based revenue is null.

Solid Biosciences Financial Statement Overview

Summary

Financials reflect an R&D-stage biotech with no revenue (2023–2025 at $0) and widening losses (net loss roughly -$96M in 2023 to about -$174M in 2025). Leverage is modest with improving debt-to-equity (~0.12 in 2025), but cash burn is heavy and worsening (operating cash flow about -$156M in 2025), implying ongoing dependence on external funding.

Income Statement

Results remain heavily loss-making with no meaningful revenue base in the most recent periods (2023–2025 show $0 revenue). Losses have widened over time (net loss of about -$96M in 2023 to about -$174M in 2025), pointing to rising operating spend without offsetting commercialization progress. The main positive is that losses appear consistent with an R&D-stage biotech profile, but overall profitability and trajectory are weak.

Balance Sheet

Leverage is modest, with debt-to-equity improving to ~0.12 in 2025 from ~0.21 in 2023, which reduces balance-sheet risk. However, returns on equity are deeply negative (about -97% in 2025), reflecting substantial ongoing losses relative to the equity base. Equity increased in 2025 versus 2024, but continued losses remain a key risk to future capitalization.

Cash Flow

Cash burn is significant and trending worse: operating cash flow declined from about -$94M (2023) to about -$156M (2025), with free cash flow similarly negative (about -$157M in 2025). A positive is that free cash flow broadly tracks net loss (free cash flow to net income ~1.0 across years), suggesting limited non-cash distortion, but the company still depends on external funding given persistent negative operating and free cash flow.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	8.09M	13.62M
Gross Profit	-1.64M	-2.46M	-2.58M	8.09M	13.62M
EBITDA	-177.57M	-121.90M	-93.43M	-96.87M	-69.29M
Net Income	-174.32M	-124.70M	-96.02M	-85.98M	-72.19M
Balance Sheet
Total Assets	232.54M	188.66M	164.94M	260.25M	232.38M
Cash, Cash Equivalents and Short-Term Investments	187.85M	148.92M	123.64M	213.72M	207.78M
Total Debt	21.16M	24.18M	26.27M	28.55M	2.06M
Total Liabilities	52.53M	51.42M	38.46M	48.59M	24.17M
Stockholders Equity	180.01M	137.25M	126.48M	211.67M	208.21M
Cash Flow
Free Cash Flow	-157.44M	-100.67M	-95.69M	-100.99M	-79.05M
Operating Cash Flow	-156.29M	-100.01M	-94.18M	-97.98M	-77.76M
Investing Cash Flow	-58.45M	-16.09M	9.69M	59.16M	-91.09M
Financing Cash Flow	194.45M	122.44M	3.12M	74.83M	134.99M

Solid Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.03
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLDB, the sentiment is Positive. The current price of 7.03 is above the 20-day moving average (MA) of 6.85, above the 50-day MA of 6.41, and above the 200-day MA of 5.73, indicating a bullish trend. The MACD of 0.31 indicates Positive momentum. The RSI at 52.51 is Neutral, neither overbought nor oversold. The STOCH value of 30.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SLDB.

Solid Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SLDB	57 Neutral	$702.51M	-2.83	-73.34%	―	―	17.88%
ADCT	54 Neutral	$514.53M	-3.14	76.03%	―	6.35%	39.57%
GLUE	54 Neutral	$1.20B	-33.72	-15.12%	―	1112.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AUTL	51 Neutral	$372.60M	-1.37	-63.76%	―	407.86%	30.35%
KRRO	47 Neutral	$162.54M	-0.64	-115.95%	―	―	21.61%

Solid Biosciences Corporate Events

Solid Biosciences Reports Encouraging Phase 1/2 Duchenne Data

On March 11, 2026, Solid Biosciences reported positive interim data from its first-in-human Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 in 40 pediatric patients with Duchenne muscular dystrophy, based on a February 23, 2026 data cutoff. The treatment was generally well tolerated under a steroid-only immunomodulation regimen across 15 sites in the U.S., Canada, Italy and the U.K., with dosing continuing.

Biopsies from 20 participants at Day 90 and three at Day 360 showed robust microdystrophin transduction and expression, along with restored beta-sarcoglycan and nNOS activity, suggesting reconstitution of critical components of the dystrophin-associated protein complex. A marked reduction in embryonic myosin heavy chain-positive fibers and decreases in multiple serum muscle damage biomarkers indicated improved muscle integrity and potential interruption of the chronic degeneration-regeneration cycle.

Cardiac assessments, initially planned for safety, showed stabilization to improvement in left ventricular ejection fraction, particularly in participants who began with low-normal systolic function, addressing a key cause of morbidity and mortality in Duchenne. Solid Biosciences also confirmed it has reached agreement with the U.S. Food and Drug Administration on the design of its Phase 3 IMPACT DUCHENNE trial of SGT-003, with screening underway and first dosing expected in the first quarter of 2026, underscoring a clear regulatory and clinical path that could strengthen the company’s position in the competitive Duchenne gene therapy landscape.

The most recent analyst rating on (SLDB) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Solid Biosciences stock, see the SLDB Stock Forecast page.

Solid Biosciences Announces $240 Million Private Placement Financing

On March 6, 2026, Solid Biosciences Inc. entered into a securities purchase agreement with institutional accredited investors for a private placement of 14,973,257 common shares at $5.61 and pre-funded warrants for 27,807,482 shares at $5.609, raising approximately $240 million in gross proceeds and $226.8 million in net proceeds, with closing expected around March 9, 2026. The deal, which includes major life sciences investors and trading lock-ups until March 11, 2026, also provides for resale registration rights and liquidated damages if registration deadlines are missed, while warrant terms cap individual ownership levels to prevent excessive concentration.

The company structured the offering as an exempt private placement to accredited and qualified institutional buyers, with the securities initially unregistered and subject to resale restrictions under U.S. federal securities laws. Based on its current operating plan, Solid Biosciences estimates that the net proceeds from this financing, combined with existing cash and investments, will fund operating and capital needs into the first half of 2028, though the company does not expect this cash runway to cover completion of development for any product candidates and may need further funding sooner if assumptions change.

The most recent analyst rating on (SLDB) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Solid Biosciences stock, see the SLDB Stock Forecast page.